ARIAD Pharmaceuticals  
Worldwide
 
Overview
 

Company News

ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
ARIAD Pharmaceuticals (August 06, 2014)
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
ARIAD Pharmaceuticals (August 05, 2014)
Daily Market Movers (24 July 2014) (July 25, 2014)
Daily Market Movers (23 July 2014) (July 24, 2014)
Weekly Market Movers (to 18 July 2014) (July 21, 2014)
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results
ARIAD Pharmaceuticals (July 16, 2014)
Daily Market Movers (14 July 2014) (July 15, 2014)
ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe
ARIAD Pharmaceuticals (July 14, 2014)
ARIAD Announces Three Key Appointments to Its Global Management Team
ARIAD Pharmaceuticals (June 23, 2014)
Daily Market Movers (12 Jun 2014) (June 13, 2014)

Displaying 10 out of a possible 775 unique stories.
Results Sorted By date
Display All Stories


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile ARIAD Pharmaceuticals (ARIA) is a Massachusetts based biotechnology company focused on development & marketing of anti-cancer drugs that function by regulating the cell signalling pathways.
Listed or Private Company Listed
Company Classification Biotechnology; Genomics
Country USA
Company Website Website
Full Company Profile Information

PARTNERING OPPORTUNITIES (Click on Product Name for Full Details)

Product Available for Partnering Opportunity Comment Available USA Available Europe Available Japan Available RoW Markets Detail
Iclusig Yes Company plans for commercialisation of ponatinib on its own in US & potentially in Europe and a regional partnership for the product in select ex-US markets. No Yes Yes Yes WW ex USA

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
24/07/2014 24 Jul: Shares rise on 3x average daily trading volume. 1,155 5.1% 57

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
ARIAD Pharmaceuticals 1 41

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


 
EP Vantage - last 6 months
Novartis sets Alk inhibitors a high bar (March 27, 2014)

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now